<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">

Poster A010: Orthotopic, Bioluminescent Syngeneic HCC Models Developed

Interrogation of Checkpoint Inhibitors in Bioluminescent Orthotopic Syngeneic Models of Hepatocellular Carcinoma

Nektaria Papadopoulou, Louise Wainwright, Vicky Lacey, Jane Wrigley, Jamie Wood, Sumanjeet Malhi, Louise Woolley, Jason King, Simon Jiang, and Rajendra Kumari

CrownBio 2017. Poster A104: Orthotopic, Bioluminescent Syngeneic HCC Models DevelopedHepatocellular carcinoma (HCC) is an aggressive cancer type with limited therapeutic treatment options. Immunotherapies such as checkpoint inhibitors are being evaluated in HCC, which therefore require suitable models for thorough preclinical development.

Subcutaneous syngeneic models are the common choice for preclinical checkpoint inhibitor assessment; however, orthotopic models have a more relevant tumor microenvironment and are more closely comparable to human disease.

CrownBio has therefore developed orthotopic, bioluminescent, syngeneic HCC models allowing non-invasive and real time tumor burden determination, and assessment of checkpoint inhibitors to treat HCC.

Read this Poster to Discover:

  • The development and characterization of Hepa 1-6 and H22 orthotopic, bioluminescent syngeneic models for preclinical efficacy assessment
  • That Hepa 1-6-lux allografts grow in the parenchyma of the liver, with a reduction in tumor burden following sorafenib treatment
  • That H22-lux allografts develop in the liver, with malignant ascites in the peritoneum, with trends towards reduced tumor burden following sorafenib or anti-CTLA-4-treatment

Download the Poster Now!

Download Now

Your privacy is important to us.
We'll never share your information.